viewInnoCan Pharma

Full interview: Innocan Pharma plans to collaborate with Tel Aviv University to find treatment for COVID-19

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver to bring news the company has entered into a sponsored research agreement with Ramot at Tel Aviv University to collaborate with Tel Aviv University to develop a novel, revolutionary approach to treating COVID-19 by using Cannabidiol loaded Exosomes.

Bincovich tells Proactive this will work in Phases and she discusses what the first part will look like and why they feel CBD could be effective in treating the Corona Virus.

Quick facts: InnoCan Pharma

Price: 0.28 CAD

Market: CSE
Market Cap: $49.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...


Innocan Pharma teams up with Endless Sky to manufacturer and distribute its...

Innocan Pharma Corporation (CSE:INNO) CEO Iris Bincovich and Endless Sky CEO Travis George tells Proactive the two have signed a manufacturing and distribution agreement. Bincovich says Endless Sky will exclusively distribute Innocan’s CBD products in Canada and manufacture them at its Health...

on 18/8/20

2 min read